# Jamey Millar

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/jamey-millar
Canonical HTML page: https://getyourbrief.com/entity/jamey-millar

## Recent coverage (2 stories, network-wide)

### Pharma's Obesity Boom: Novo Nordisk's 70% Volume Surge Raises Energy Footprint Questions
2026-08-10 22:52:11 · Sector: climate · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Novo Nordisk’s soaring obesity drug volumes—up 70% year-over-year—signal escalating demand for energy-intensive pharmaceutical manufacturing. While expanding access to GLP-1 therapies may reduce long-term healthcare burdens, the immediate production ramp-up presents sustainability challenges that the pharma sector must address.
Full story: https://getclimatebrief.com/story/novo-nordisk-obesity-manufacturing-energy-climate

### Wegovy Pill at 267K Weekly Scripts, 90% of U.S. Oral Obesity Market—Novo Nordisk Q2
2026-08-10 22:51:34 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Full story: https://getbiobrief.com/story/novo-nordisk-q2-wegovy-pill-obesity-boom-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.